Top 50 Medical Startup Investors in Switzerland (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Zürcher Kantonal Bank
VC Fund
|
19 | Switzerland, Germany, Japan | Seed, Series A | Health Care, Medical Device, Biotechnology | $1.2M–$14M |
|
Verve Ventures
VC Fund
|
13 | Switzerland, Germany, France | Series A, Seed, Series B | Health Care, Software, Biotechnology | $1.4M–$43M |
|
Foundation for Innovation and Technology (FIT)
VC Fund
|
10 | Switzerland, France, United States | Debt Financing, Grant, Seed | Health Care, Biotechnology, Information Technology | $23k–$1.2M |
|
StartAngels Network
VC Fund
|
6 | Switzerland, Brazil | Seed, Series A, Series B | Medical, Health Care, Medical Device | $933k–$6.1M |
|
BioMedPartners
VC Fund
|
6 | Switzerland, Germany, France | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.9M–$83M |
|
Sofinnova Partners
VC Fund
|
5 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6M–$120M |
|
BlueOcean Ventures
VC Fund
|
5 | Switzerland, India, France | Seed, Series A | Health Care, Medical, Personal Health | $1M–$20M |
|
SICTIC
VC Fund
|
5 | Switzerland, Germany, United Kingdom | Seed, Pre-Seed | Software, Artificial Intelligence, Information Technology | $233k–$2.9M |
|
Swisscom Ventures
VC Fund
|
5 | Switzerland, United States, United Kingdom | Series B, Series A | Software, SaaS, Information Technology | $1.8M–$59M |
|
OrbiMed
VC Fund
|
4 | United States, China, Israel | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $10M–$150M |
|
Schroder Adveq
VC Fund
|
4 | Switzerland, United States, India | Series B, Series C, Series A | Biotechnology, Health Care, Therapeutics | $5.6M–$100M |
|
Versant Ventures
VC Fund
|
4 | United States, Switzerland, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $4.7M–$108M |
|
4FO Ventures
VC Fund
|
4 | Switzerland | Series A, Seed, Series B | Medical, Health Care, Biotechnology | $2.1M–$54M |
|
GoBeyond
VC Fund
|
4 | Switzerland, Germany, United Kingdom | Seed, Series A | Information Technology, Medical, Software | $544k–$10M |
|
Polytech Ventures
VC Fund
|
4 | Switzerland, United States, Spain | Seed, Series A | Financial Services, FinTech, Software | $1M–$9.7M |
|
New Enterprise Associates
VC Fund
|
4 | United States, India, United Kingdom | Series A, Series B, Series C | Software, Health Care, Biotechnology | $5.3M–$103M |
|
Fongit Seed Invest
VC Fund
|
4 | Switzerland | Seed, Series A, Series B | Health Care, Medical, Biotechnology | $1.2M–$3.7M |
|
Sunstone Life Science Ventures
VC Fund
|
4 | Denmark, Sweden, Switzerland | Series B, Series A | Biotechnology, Health Care, Medical | $5.5M–$52M |
|
3wVentures
VC Fund
|
4 | Switzerland, Spain, Austria | Seed, Angel, Series A | Software, Health Care, Medical | $50k–$8M |
|
Kickfund
VC Fund
|
4 | Switzerland, Germany | Seed, Pre-Seed, Convertible Note | Manufacturing, Medical, Health Care | $109k–$6M |
|
Zühlke Ventures AG
VC Fund
|
4 | Switzerland, Sweden, United States | Series A, Seed, Series B | Health Care, Medical Device, Medical | $1.2M–$11M |
|
Bernina BioInvest
VC Fund
|
4 | Switzerland | Seed, Series A, Series B | Biotechnology, Health Care, Biopharma | $1.7M–$65M |
|
Eclosion SA
VC Fund
|
4 | Switzerland | Seed, Series C | Biotechnology, Pharmaceutical, Health Care | $1.6M–$28M |
|
Endeavour Vision
VC Fund
|
3 | United States, Switzerland, France | Series C, Series B, Series A | Health Care, Medical, Biotechnology | $2.1M–$115M |
|
Fuho Capital
VC Fund
|
3 | China, Switzerland | Series A, Angel, Series B | Health Care, Biotechnology, Medical | $425k–$44M |
|
Founderful
VC Fund
|
3 | Switzerland, United Kingdom, Canada | Pre-Seed, Seed, Series A | Software, Artificial Intelligence, Information Technology | $1.1M–$24M |
|
EIT Health
VC Fund
|
3 | United Kingdom, Spain, Ireland | Grant, Pre-Seed, Seed | Health Care, Medical Device, Medical | $22k–$1.6M |
|
VINCI CAPITAL
VC Fund
|
3 | Switzerland, Germany | Series A, Series B | Medical, Health Care, Biotechnology | $8.6M–$36M |
|
Broadview Ventures
VC Fund
|
3 | United States, Switzerland, Canada | Series A, Seed, Series B | Health Care, Biotechnology, Medical Device | $1M–$45M |
|
EQT Life Sciences
VC Fund
|
3 | United States, The Netherlands, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $6.9M–$165M |
|
Index Ventures
VC Fund
|
3 | United States, United Kingdom, France | Series A, Series B, Seed | Software, E-Commerce, Internet | $1.3M–$100M |
|
Innosuisse
VC Fund
|
3 | Switzerland, United States, United Kingdom | Grant, Pre-Seed, Seed | Health Care, Biotechnology, Medical Device | $17k–$16M |
|
Alpana Ventures
VC Fund
|
3 | United States, Switzerland, Germany | Seed, Series A | Software, FinTech, Information Technology | $850k–$14M |
|
XtalPi
VC Fund
|
3 | China, United States, Japan | Series A, Seed, Angel | Biotechnology, Health Care, Pharmaceutical | $1.4M–$30M |
|
Gilde Healthcare
VC Fund
|
3 | United States, The Netherlands, Germany | Series B, Series C, Series A | Biotechnology, Health Care, Medical | $8.8M–$120M |
|
M Ventures
VC Fund
|
3 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Inserm Transfert Initiative
VC Fund
|
3 | France, Switzerland, United States | Series A, Series B, Seed | Biotechnology, Medical, Health Care | $1.1M–$60M |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
2 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.3M–$50M |
|
Lichtsteiner Foundation
VC Fund
|
2 | Switzerland | Seed, Series A | Biotechnology, Health Care, Medical | $1.6M–$7.2M |
|
The William K. Warren Foundation
VC Fund
|
2 | United States, Switzerland | Seed, Series A, Series B | Machine Learning, Health Care, Artificial Intelligence | |
|
ORTHO INNOVATIONS
VC Fund
|
2 | Switzerland | Seed | Medical, Health Care, Biotechnology | |
|
Healthspan Capital
VC Fund
|
2 | Germany, Switzerland, United States | Seed | Health Care, Biotechnology, Medical | |
|
Calm/Storm Ventures
VC Fund
|
2 | United Kingdom, Germany, Austria | Seed, Pre-Seed, Series A | Health Care, Wellness, Software | |
|
Novartis Venture Fund
VC Fund
|
2 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | |
|
Grazia Equity
VC Fund
|
2 | Germany, United States, Switzerland | Series A, Series B, Seed | Internet, E-Commerce, Biotechnology | |
|
Boundary Holding
VC Fund
|
2 | Switzerland, India, France | Seed, Series A | Drones, Robotics, Artificial Intelligence | $18k–$4.7M |
|
Baszucki Group
VC Fund
|
2 | Switzerland | Seed | Medical, Health Care, Biotechnology | |
|
Reference Capital SA
VC Fund
|
2 | United States, Switzerland, United Kingdom | Series A, Series C, Series B | Software, Health Care, Biotechnology | |
|
R42 Group
VC Fund
|
2 | United Kingdom, United States, Austria | Seed, Pre-Seed | Biotechnology, Health Care, Information Technology | |
|
Viva BioInnovator
VC Fund
|
2 | United States, Canada, China | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $250k–$100M |
| Access all 432 investors in Switzerland Medical startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Zürcher Kantonalbank is an independent, incorporated public-law institution is its public service mandate. Enshrined in law, it governs the bank's economic, social, and environmental commitment.
Show more...Investment focus
- Industry: Health Care, Medical Device, Biotechnology
- Stage:Seed, Series A
- Geography: Switzerland, Germany, Japan
Investor stats
- Total investments: 187
- Round size: Seed $1.2M–$6M; Series A $2.3M–$14M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- TestResults — TestResults uses the TrueTest technology and AI-based virtual user that makes it possible for the first time to test autonomously across software, system, and technology boundaries from a user perspective with the same approach. The company has simplified automated testing massively and reduced time radically. With it, the automation andmaintenance effort is reduced to a minimum that allows zero flakiness and the enlightening feeling of being in control of automation and test scenarios.
- QualySense — QualySense is a Swiss start-up company focused on innovative high-throughput grain, beans and seeds sorting technology. QualySense develops a high-speed multi-tons per hour sorting device, which will change how grains, beans and seeds are processed and valued worldwide by assessing the biochemical quality of grains one by one. The QualySensesorters will enable customers to separate grain batches into different biochemical quality classes and sell the corresponding premium products at higher average prices. Food processors will be able to considerably increase the production value, and produce higher quality products in a non-interrupted process.
- Pearltec AG — Headquartered in Schlieren / Zurich, Pearltec AG develops, produces and delivers solutions for the optimal storage, fixation and positioning of patients. Their products are based on unique, patented technology developed in collaboration with ETH Zurich and renowned university hospitals.They have set theirselves the goal to use the technologycompetence of Pearltec AG for the benefit of humans, animals and industry and to create added value for their customers by excellent quality and convincing application advantages.Pearltec AG is certified according to ISO standard 13485. This certification certifies that their quality management system for the development and manufacture of medical devices meets the highest international standards.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 260
- Round size: Seed $1.4M–$10M; Series A $2.3M–$17M; Series B $4.2M–$43M
- Lead/follow: 14% lead, 86% follow
- Last fund: Likely still investing — raised $66M in 2022
Portfolio highlights
- Sleepiz — Sleepiz is a Zürich based startup with the aim to enable the medical community to take healthcare into the home environment. Sleepiz provides an easy and comfortable to use solution with a device that is simply placed on the bedside table. The device operates in a non-contact fashion and measures movements originating from heart contractions andbreathing patterns as well as body motions with medical grade accuracy.By making use of wireless millimeter wave technology, sensor fusion and artificial intelligence Sleepiz will in the future not only able to diagnose sleep disorders, but also to perform long-term monitoring. Thereby, the progression of chronic diseases can be monitored to allow faster intervention and better treatment.
- Biograil — Biograil, founded in 2019 and led by CEO Karsten Lindhardt, is using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The Biograil device avoids mechanical moving components and makes use of the body’s own peristaltic forces to facilitate the delivery ofthe biologic efficiently into the gastrointestinal wall.
- iMusician — iMusician offers music distribution, promotion, mastering, and monetization for independent musicians & labels. Get on Spotify, Apple Music, Amazon, TikTok & many more.
The Foundation for Technology Innovation gives financial assistance to creative and technological projects at various phases of development. FIT funds projects in energy and the environment, information and digital technology, life sciences and health, precision industries, and nutrition and agriculture.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Information Technology
- Stage:Debt Financing, Grant, Seed
- Geography: Switzerland, France, United States
Investor stats
- Total investments: 167
- Round size: Seed $117k–$1.2M; Grant $23k–$125k; Debt Financing $100k–$583k
- Lead/follow: 93% lead, 7% follow
Portfolio highlights
- Phonemia — Phonemia is a digital health company that offers artificial intelligence and speech therapy services.
- MoleSense — Developing continuous molecular monitoring wearables to enable proactive healthcare.
- DiverSsiTy SA — DiverSsiTy SA develops personalized, patient-centric digital health technologies (DHTs) to improve the lives of patients suffering from neurodevelopmental disorders (NDDs), among which are those with autism spectrum disorder (ASD) and related comorbidities like attention-deficit/hyperactivity disorder (ADHD).
StartAngels Network is a Zurich-based angel investment firm that provides investment consulting services.
Show more...Investment focus
- Industry: Medical, Health Care, Medical Device
- Stage:Seed, Series A, Series B
- Geography: Switzerland, Brazil
Investor stats
- Total investments: 26
- Round size: Seed $933k–$3.7M; Series A $2.1M–$3.7M; Series B $1.7M–$6.1M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- Calingo — Calingo is a digital insurance platform that offers personalised and optimised risk protection at the point of sale.
- Scanvio — Scanvio Medical provides gynecologists, endometriosis centers and ultrasound manufacturers with an AI-guided ultrasound software for faster endometriosis diagnosis.
- Hylomorph — Hylomorph is a clinical-stage medical device company developing innovative materials designed to transform the biocompatibility of implantable medical devices.
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Switzerland, Germany, France
Investor stats
- Total investments: 87
- Round size: Series A $5.3M–$26M; Series B $4.9M–$83M; Series C $5.8M–$48M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $113M in 2018
Portfolio highlights
- Vaximm — Vaximm is focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Their initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. Vaximm has shown impressive anti-tumor activity in various animal studies and will enter first human clinicaltrials in 2011.
- iDEL Therapeutics — iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.
- Affimed — At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim toovercome the limitations and challenges faced by current immuno-oncology (I-O) therapies.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 309
- Round size: Series A $6M–$67M; Series B $10M–$120M; Series C $12M–$100M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Elicit Plant — We work with farmers around the world to meet the challenges of climate change and the impact of water scarcity on field crops.
- l'école — l'école AI is a computer vision-focused development platform. Its objective is to enable humans to use AI with purpose to change the future, beginning with a focus on speeding advances in life sciences using computer vision.
- EndoRon Medical — Endoron Medical develops an endovascular suture, like a device for the effective treatment of an abdominal aortic aneurysm.
BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.
Show more...Investment focus
- Industry: Health Care, Medical, Personal Health
- Stage:Seed, Series A
- Geography: Switzerland, India, France
Investor stats
- Total investments: 17
- Round size: Seed $1M–$3M; Series A $2.3M–$20M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Augurix — Just another WordPress site
- Mikajaki — Mikajaki is an innovative automated multi-patient ocular diagnostics platform. The platform enables the use of digital technology, robots, AI, and data, allowing patients and eye specialists access to the specific treatment they require. Mikajaki is currently collaborating with ophthalmology clinic groups across the world to test and implementEyeLib.
- official.fm — At Official.fm, they develop powerful music promotion tools for you, whether you're an emerging artist or an accomplished label.They make it easy to manage a few tracks or a large catalog, create pages and players that look like you and share them across your favorite promotion platforms and social networks, all the while collectinginsightful analytics. Improving your workflow is their top priority.Promoting your music with official.fm will always be free. Music promotion is an investment for you and it is one for us too. Now you also have the ability to sell directly music to your fans. Soon they will offer more ways for your to generate revenue from your music.
SICTIC is the leading angel investor network in Switzerland with the largest Swiss seed-stage startup dealflow.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed
- Geography: Switzerland, Germany, United Kingdom
Investor stats
- Total investments: 128
- Round size: Seed $583k–$2.9M; Pre-Seed $233k–$2.1M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Qala — Qala delivers real-time data classification, discovery, and policy enforcement. Auto-classify sensitive data, map full lifecycles, and label at source.
- hypt — hypt is a Swiss based SaaS marketing solution that empowers companies to digitalize word-of-mouth. By using our word-of-mouth manager companies are able to activate 40% of their customers to send out a personal recommendation to their peers increasing sales through word-of-mouth by 4 times. Our solution empowers our ICP customers in the finance andinsurance segments to strategically use and optimize the most authentic and cost effective advertising channel – word-of-mouth – and makes it an accessible asset of every marketing mix.
- Ionic Wind Technologies — Ionic wind technologies, which use an internationally patented concept, alter the way airflow is generated. Instead of conventional rotating machinery, we move air with electric fields.
Swisscom Ventures is an venture capital arm of Swisscom AG, that specializes in early stage tech investments founded in 2007.Swisscom Ventures invests in growth companies with emerging business models and technologies of strategic relevance to Swisscom's core business. As a value-add investor, Swisscom brings its investees the technicalexpertise and strategic insights of an incumbent telecom operator. We act as a bridge to Swisscom's operational business units, which portfolio companies can also leverage as a test environment for their products and services.Swisscom Ventures seeks minority stakes in companies related to the information/communications/entertainment space.
Show more...Investment focus
- Industry: Software, SaaS, Information Technology
- Stage:Series B, Series A
- Geography: Switzerland, United States, United Kingdom
Investor stats
- Total investments: 142
- Round size: Series A $1.8M–$23M; Series B $2.3M–$59M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely still investing — raised $300M in 2022
Portfolio highlights
- Bring! Labs — Bring! Labs is an app for multi-device use that accompanies the user through all aspects of shopping for groceries and other everyday items. It offers grocery shopping for millions of people with shared shopping lists, integrated recipes, online shopping, local offers, and loyalty cards. Bring! Labs offers innovative mobile advertising platforms tocompanies in the retail and FMCG.
- Kandou AI — We enable faster and more energy efficient interconnects with a smaller physical footprint than competing technologies. Our chip connection technologies improves the speed to power consumption trade-off frontier.
- amnis — Check out your possibilities to transfer money abroad, collect international payments and exchange currencies all in one account. Make payments fast with amnis.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, China, Israel
Investor stats
- Total investments: 589
- Round size: Series A $10M–$116M; Series B $24M–$150M; Series C $15M–$143M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Sonendo — Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.
- Crown Bioscience — Crown Bioscience is an expert preclinical contract research organization providing oncology services and preclinical cancer models for drug development. Crown Biocience brings clarity to drug discovery worldwide, helping companies solve today's most pressing problems in immuno-oncology, oncology, cardiovascular, and metabolic diseases.
- Aspen Neuroscience — personalized cell therapy Starts with you Learn More about our technology
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Schroders Capital provides investors with access to a broad range of private asset investment opportunities, portfolio building blocks and customised private asset strategies. With over $65 billion assets under management, we offer a diversified range of investment strategies, including real estate, private equity, secondaries, venture capital, infrastructure, securitised products and asset-based finance, insurance-linked securities and impact investing.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series C, Series A
- Geography: Switzerland, United States, India
Investor stats
- Total investments: 36
- Round size: Series A $5.6M–$23M; Series B $11M–$83M; Series C $15M–$100M
- Lead/follow: 11% lead, 89% follow
- Last fund: May invest from a new fund soon — raised $113M in 2020
Portfolio highlights
- Bizongo — Bizongo is a Tech-Enabled B2B Platform for Packaging, Apparels & Other Customised Goods. We digitally transform vendor management & supply chain.
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
- Memo Therapeutics — Memo Therapeutics AG translate immune responses into superior medicines. Our best-in-class antibodies transform lives of patients with viral infections & cancer
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, Canada
Investor stats
- Total investments: 282
- Round size: Series A $4.7M–$80M; Series B $10M–$105M; Series C $12M–$108M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Stablix — Stablix is pioneering an entirely new field of targeted protein stabilization (TPS) to bring transformative medicines to patients with unmet medical need.
- Passage Bio — Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their families.
- Lycia Therapeutics — Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA.
4FO Ventures
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Switzerland
Investor stats
- Total investments: 15
- Round size: Seed $2.1M–$3.6M; Series A $2.1M–$15M; Series B $6.4M–$54M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- Positrigo — NeuroLF is an ultra-compact brain Positron Emission Tomography system. Our technology makes functional imaging accessible for people worldwide.
- Ecorobotix — ecoRobotix contributes to an agriculture that respects the environment, focusing on soil and hydrological resources conservation and using a minimum amount of energy. ecoRobotix aims to offer precise, safe, reliable and affordable robotic solutions that simplify farmers’ life to produce healthy food. In particular, its revolutionary solar-poweredweeding robot offers a more sustainable use of herbicides while reducing farmers costs.
- ARTIRIA Medical — Artiria Medical empowers catheters and guidewires. We develop cutting edge technologies to revolutionize the limits of neurointerventional procedures, enabling a seamless navigation and stroke treatment.
GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.
Show more...Investment focus
- Industry: Information Technology, Medical, Software
- Stage:Seed, Series A
- Geography: Switzerland, Germany, United Kingdom
Investor stats
- Total investments: 163
- Round size: Seed $544k–$5M; Series A $1.2M–$10M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Fastree3D — Fastree3D imaging sensors help recognize and measure distance to fast moving objects in real-time, enabling driving assistance or autonomous navigation. Fastree3D SA is a fabless semiconductor company, spin-off from EPFL Lausanne, Switzerland founded in September 2013 (UID CHE-291.330.490). The company subsidiary Fastree3D B.V. performs researchwith TU-Delft, Netherlands (KvK 58866973).
- Spyra One — Single Shot Technology | Tactical display | Automatic Refill | Power Shot SpyraTwo - the world's strongest water gun! Start epic water battles with the only water gun in the world that features our patented Single-Shot-Technology, fully automatical pump, a hightech tactical display and the Power Shot for extra impact.
- Arktis Radiation Detectors — Arktis develops and manufactures next generation systems that detect and categorize radiological and nuclear materials to enhance security and operations.
Polytech Ventures are an early stage VC firm based in Switzerland with a strong international focus. Their strategic location at EPFL in Lausanne grants us access to one of the most dynamic and recognized innovation centers in the world
Show more...Investment focus
- Industry: Financial Services, FinTech, Software
- Stage:Seed, Series A
- Geography: Switzerland, United States, Spain
Investor stats
- Total investments: 50
- Round size: Seed $1M–$5M; Series A $2.3M–$9.7M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $40M in 2016
Portfolio highlights
- Relai — All you need to get started is to download our award winning Relai app, complete a simple verification and start buying with as little as 50 CHF/EUR.
- Hemostod — Developing universal platelets and next-generation diagnostics
- Earny — Payroll management built for Startups & SMEs. Swiss payroll service with no hidden fees & no hassle
Foundational partners to ambitious founders at every stage of company-building.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1539
- Round size: Series A $5.3M–$60M; Series B $10M–$80M; Series C $13M–$103M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — raised $2.8B in 2022
Portfolio highlights
- Perplexity — Perplexity is a search engine platform that uses artificial intelligence to provide large language models and search engines. The company's platform enables the development of beneficial artificial general intelligence, as well as an open-source environment that is accessible to the public, allowing clients to develop skills and knowledge inartificial intelligence.
- Allay Therapeutics — SUPPORTING PATIENTS THROUGH EVERY PHASE OF RECUPERATION The first technology designed to deliver weeks of localized pain management
- Regulus Therapeutics — Regulus Therapeutics Is a biopharmaceutical company leading the discovery of a new class of high-impact medicines based on microRNAs. The discovery of MicroRNA in humans is one of the most exciting scientific breakthroughs in the last decade. MicroRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteinsbut instead regulate gene expression. It was founded in 2007 and is headquartered in Carlsbad, California.
Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: Switzerland
Investor stats
- Total investments: 9
- Round size: Seed $1.2M–$1.4M; Series A $2.3M–$3.7M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
- Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
- Annaida Technologies — Empowering fertility providers and researchers with AI-driven metabolomic platforms. Non-invasive, real-time insights at the microscale for personalized medical treatments.
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: Denmark, Sweden, Switzerland
Investor stats
- Total investments: 56
- Round size: Series A $5.5M–$43M; Series B $9.6M–$52M
- Lead/follow: 14% lead, 86% follow
- Last fund: May invest from a new fund soon — raised $94M in 2019
Portfolio highlights
- Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
- Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
3wVentures provides seed money and venture capital to international internet startups. As they focus on early stage projects and prototypes, our investments and co-investments target a volume of up to USD 250,000.
Show more...Investment focus
- Industry: Software, Health Care, Medical
- Stage:Seed, Angel, Series A
- Geography: Switzerland, Spain, Austria
Investor stats
- Total investments: 42
- Round size: Seed $50k–$3.8M; Angel $583k–$2.1M; Series A $1.2M–$8M
- Lead/follow: 2% lead, 98% follow
- Last fund: May invest from a new fund soon — raised $100M in 1999
Portfolio highlights
- Abionic — Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergyprofiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.Abionic appreciates the support it has received from:
- GUURU Solutions — Discover how community-powered advice can turn your PDPs into trusted, high-converting content and get cited in AI search.
- Pregnolia — Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete theclinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.
Kickfund is a Venture Capital fund that systematically backs companies that successfully complete Venture Kick.
Show more...Investment focus
- Industry: Manufacturing, Medical, Health Care
- Stage:Seed, Pre-Seed, Convertible Note
- Geography: Switzerland, Germany
Investor stats
- Total investments: 37
- Round size: Seed $1.7M–$6M; Pre-Seed $335k–$4.4M; Convertible Note $109k–$121k
- Lead/follow: 8% lead, 92% follow
Portfolio highlights
- Rhovica Neuroimaging — Rhovica Neuroimaging is a rapid and safe placement of an external ventricular drain (EVD) and is a lifesaving emergency procedure. EVDs are thin catheters, that are inserted into the brain cavities (ventricles) for fluid drainage to decrease intracranial pressure (ICP) and for measurement of ICP.
- Cosaic — Cultivated - Creamy, dairy-free indulgence
- Ionic Wind Technologies — Ionic wind technologies, which use an internationally patented concept, alter the way airflow is generated. Instead of conventional rotating machinery, we move air with electric fields.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Zühlke Ventures AG is a venture capital arm of Zühlke Technology Group AG specializing in financing of start-ups at an early stage and providing growth capital. It seeks to invest in the technology and medical devices companies. It typically invests in German-speaking Europe and Great Britain.
Show more...Investment focus
- Industry: Health Care, Medical Device, Medical
- Stage:Series A, Seed, Series B
- Geography: Switzerland, Sweden, United States
Investor stats
- Total investments: 12
- Round size: Seed $1.2M–$3M; Series A $7M–$11M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Evismo — Diagnosing arrhythmias, sleep apnea, and stress directly in your practice. Digitally and efficiently. For general practitioners and specialists in Switzerland.
- Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
- PeriVision — At Perivision, we combine artificial intelligence (AI), virtual reality (VR) and the cloud to build the next generation systems to understand visual function. Our systems improve workflow efficiency in practices and hospitals and provide deeper clinical insight into eye diseases.
Bernina BioInvest is an investment Firm.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Biopharma
- Stage:Seed, Series A, Series B
- Geography: Switzerland
Investor stats
- Total investments: 10
- Round size: Seed $1.7M–$20M; Series A $17M–$65M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
- Memo Therapeutics — Memo Therapeutics AG translate immune responses into superior medicines. Our best-in-class antibodies transform lives of patients with viral infections & cancer
- Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Health Care
- Stage:Seed, Series C
- Geography: Switzerland
Investor stats
- Total investments: 16
- Round size: Seed $1.6M–$2.7M; Series C $20M–$28M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
- Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
- MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases
Endeavour Vision is an investment advisory firm focused on transformative healthcare technologies.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series C, Series B, Series A
- Geography: United States, Switzerland, France
Investor stats
- Total investments: 69
- Round size: Series A $2.1M–$30M; Series B $7M–$45M; Series C $12M–$115M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $375M in 2021
Portfolio highlights
- Gynesonics — Gynesonics is a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions. Gynesonics serves customers worldwide. It was founded in 2005 and is headquartered in Redwood City, California.
- Kenbi — Lovable Generated Project
- Relievant Medsystems — Get proven, long-term relief from chronic vertebrogenic low back pain with Intracept, a minimally invasive, one-time procedure.
Fuho Capital is an equity investment fund management company.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Angel, Series B
- Geography: China, Switzerland
Investor stats
- Total investments: 32
- Round size: Angel $425k–$2.8M; Series A $709k–$29M; Series B $2.8M–$44M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Leman Biotech — Leman Biotech is a biotech company that is engaged in development of cancer immunotherapies.
- Euregen Biopharma — Euregen Biopharma is a pharmaceutical company that specializes in the innovation and development of synthetic lethal drugs for tumors.
- Mainstream Biotech — Mainstream Bio is a biotechnology company grounded in research, specializing in the development of innovative peptide therapeutics 2.0.
Founderful operates as a venture capital firm and a Switzerland’s leading pre-seed fund.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: Switzerland, United Kingdom, Canada
Investor stats
- Total investments: 97
- Round size: Seed $1.5M–$16M; Pre-Seed $1.1M–$3.8M; Series A $3.4M–$24M
- Lead/follow: 55% lead, 45% follow
- Last fund: Likely still investing — raised $85M in 2024
Portfolio highlights
- Sparkli — Sparkli offers an AI-powered educational platform that turns children’s questions into interactive learning journeys called “expeditions.” The platform generates multimodal content blending visuals, audio narration, games, and quizzes to help learners explore topics and build skills like design thinking, financial literacy, sustainability, andemotional intelligence. It personalizes experiences using generative AI so that young learners engage with content aligned to their curiosity and interests. Sparkli also includes features to track progress and encourage regular engagement through challenges, rewards, and creative reflections. The platform supports both individual exploration and guided learning contexts for children.
- Ascento — Secure, maintain, and inspect outdoor assets by reducing the intervention times and augmenting data capturing capability.
- CareerLunch — CareerLunch is a recruitment platform that pairs potential hires with employees through informal exchanges over lunch. It was founded in 2019 by Simon Hofer and Konstantin Nesterov.
EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives.
Show more...Investment focus
- Industry: Health Care, Medical Device, Medical
- Stage:Grant, Pre-Seed, Seed
- Geography: United Kingdom, Spain, Ireland
Investor stats
- Total investments: 95
- Round size: Seed $220k–$1.4M; Grant $22k–$1.6M; Pre-Seed $44k–$1.4M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- IDOVEN — IDoven develops products to detect heart problems at an early stage to prevent heart diseases.
- eBreathie — eBreathie is a pioneering digital health startup offering an integrated asthma management solution. Our system comprises a smart inhaler (a medical device) that not only tracks WHEN patients take their medication but also HOW they do it, creating a detailed inhalation profile for each use. Paired with a user-friendly mobile app for patients and acomprehensive patient management platform for doctors, we provide real-time feedback on inhalation efficacy, ensuring patients and healthcare professionals have the insights needed for optimal asthma management. Leveraging IoT and AI, our goal is to reduce emergency visits, asthma attacks, and hospitalizations while ensuring effective inhalation techniques and optimal patient care.
- Trak — Trak is a software tool for healthcare professional to provide AI-based tele-rehabilitation services like physiotherapy and others.
Vinci Capital is a leading Swiss private equity firm with over MCHF 200 under management. Since 1998 they have provided equity to over 30 Swiss technology and industrial companies to finance innovation, growth and succession-buyouts.Their investment team capitalizes on 40 years of cumulated experience in private equity and a solid operationalbackground in growth, turn-around, consolidation, IPOs and M&A situations.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Series B
- Geography: Switzerland, Germany
Investor stats
- Total investments: 15
- Round size: Series A $8.6M–$20M; Series B $21M–$36M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $10M in 2012
Portfolio highlights
- Anergis — Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland.
- SENSIMED — Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best beused in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland.
- Beqom — beqom is a Total Compensation Management Software Solution focused exclusively on managing compensation & performance for HR & Sales.
Broadview Ventures, Inc. (Broadview) was established in 2008 as a new program conceived by the Leducq family. Through Broadview, the trust will work to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investment in and support of early stage technology ventures.The FoundationLeducq, based in Paris, France, is the beneficiary of a charitable trust. In order to further the Foundation Leducq's mission in cardiovascular and neurovascular disease, the trust has made funds available to Broadview to develop a program which will promote early state technology in these fields through investments, licensing agreements and consortium funding arrangements, as well as professional, management and consulting support.With this initiative the trust joins other leaders in the venture philanthropy movement in seeking creative solutions to the problem of what is commonly referred to as the 'translational gap', a significant component of which is a lack of funding at a critical moment in the development of new technology and science.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Seed, Series B
- Geography: United States, Switzerland, Canada
Investor stats
- Total investments: 77
- Round size: Seed $1M–$9.8M; Series A $1M–$30M; Series B $7M–$45M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- FineHeart — Our mission is to address the unmet need of patients with sever heart failure
- 480 Biomedical — 480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown,Massachusetts.
- Adient Medical — Medical Devices that Automatically Vanish - Adient Medical is leading the development of an absorbable vascular filter for the prevention of pulmonary embolism.
Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, The Netherlands, Switzerland
Investor stats
- Total investments: 174
- Round size: Series A $6.9M–$77M; Series B $12M–$103M; Series C $12M–$165M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $266M in 2023
Portfolio highlights
- Perfuze — Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.
- Neuros Medical — Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgicalpain, and chronic migraine.
- Simplify Medical — Simplify Medical designs, develops, and manufactures cervical artificial discs for use in the spine. It offers an MRI compatible motion preserving artificial cervical disc that is used to treat single level symptomatic cervical disc disease.The company provides its products for skeletally mature patients for reconstruction of the disc at onelevel from C3-C7 following single-level discectomy for intractable radiculopathy, such as arm pain or a neurological deficit.Simplify Medical was founded in 2015 and is based in Mountain View, California.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Index Ventures is an international venture capital firm with dual headquarters in San Francisco and London, investing in technology-enabled companies with a focus on e-commerce, fintech, mobility, gaming, infrastructure/AI, and security.
Show more...Investment focus
- Industry: Software, E-Commerce, Internet
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 1090
- Round size: Seed $1.3M–$12M; Series A $5M–$35M; Series B $10M–$100M
- Lead/follow: 44% lead, 56% follow
- Last fund: May invest from a new fund soon — raised $117M in 2015
Portfolio highlights
- Ozon — leading e-commerce platform in Russia, first russian marketplace
- Personio — Personio is the Intelligent HR platform for companies from 10-5,000 employees, powering over 1 million people worldwide. Book your free demo today.
- Culture Amp — Culture Amp was founded as a result of its members' first hand experiences with the challenge that fast growing organizations face when their core business expands faster than its people can adapt. With years of experience in enterprise organizations, CultureAmp's team has taken more than a walk in your shoes–they've been running inthem. They look to seize an opportunity for a new type of technology- technology that amplifies learning and drives culture, instead of hindering it.
Innosuisse’s role is to promote science-based innovation in the interests of industry and society in Switzerland.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Grant, Pre-Seed, Seed
- Geography: Switzerland, United States, United Kingdom
Investor stats
- Total investments: 222
- Round size: Seed $500k–$16M; Grant $51k–$2.9M; Pre-Seed $17k–$4.3M
- Lead/follow: 81% lead, 19% follow
Portfolio highlights
- Sparkli — Sparkli offers an AI-powered educational platform that turns children’s questions into interactive learning journeys called “expeditions.” The platform generates multimodal content blending visuals, audio narration, games, and quizzes to help learners explore topics and build skills like design thinking, financial literacy, sustainability, andemotional intelligence. It personalizes experiences using generative AI so that young learners engage with content aligned to their curiosity and interests. Sparkli also includes features to track progress and encourage regular engagement through challenges, rewards, and creative reflections. The platform supports both individual exploration and guided learning contexts for children.
- OrthoSens — OrthoSens develops battery-free sensors that turn standard orthopedic implants into smart, data-driven devices. Unlike existing smart implant solutions that require an implanted battery making them too large and too risky to scale beyond large joints, OrthoSens moves all electronics outside the body. A paper-thin sensor integrates directly intoexisting implants with no battery, no surgical workflow change and zero explant risk. An external wearable powers the sensor wirelessly and collects real-time data on load, micromotion and bone fusion. The result is a footprint 250x smaller than battery-powered competitors, opening up additional spine, foot & ankle markets that existing solutions cannot address. The clinical need is clear: approximately 20% of post-surgical patients drive around 68% of total post-operative costs through missed complications, continuous implant monitoring exists to catch them earlier. Starting January 2026, 745 US hospitals enrolled in CMS's mandatory TEAM bundle are now accountable for 30-day episode costs, creating direct institutional demand for this data.OrthoSens generates revenue through three streams: sensor sales to orthopedic implant manufacturers (unlocking +$1,309 NTAP reimbursement per unit), a SaaS subscription capturing 40% of Medicare's $104/month RPM reimbursement per patient and post-market data analytics. The company has validated its technology across 3 functional prototypes, filed 2 core patents with favorable Freedom to Operate and secured $1.3M+ in non-dilutive funding. It is raising a $2.3M seed round to complete ISO-13485 certification, conduct the FDA pre-clinical study and file a 510(k) submission. The team is led by Gwenael Hannema (3x medtech founder), Dr. Oleg Kotsur (Head of R&D), and key employees, supported by experienced board members with leadership backgrounds at Novartis, Medtronic and J&J MedTech.
- Reverso Therapeutics — Reverso medicines is a biotechnology company that offers therapeutic medicines for anticoagulant therapy.
Alpana Ventures is a Swiss VC focusing on digital transformation.Since 2016 we backed 45 founder teams with 3 Funds, supporting them in their journey towards a positive impact.Committed to value creation, we discover deep tech solutions in Switzerland, Europe and the US.We invest to embed them into innovative business models and back them tobecome global market leaders.Applying ESG criteria, our portfolio companies help create a more sustainable future.
Show more...Investment focus
- Industry: Software, FinTech, Information Technology
- Stage:Seed, Series A
- Geography: United States, Switzerland, Germany
Investor stats
- Total investments: 97
- Round size: Seed $850k–$4M; Series A $2.3M–$14M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
- Nezasa — Discover how to grow your business with Nezasa TripBuilder, the world's leading travel commerce solution for travel businesses.
- Tinamu — Trusted inventory intelligence delivered in real-time
XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform. Through its tightly interwoven quantum mechanics, artificial intelligence, and high-performance cloud computing algorithms, the ID4 platform enablespharmaceutical companies to increase their efficiency, accuracy, and success rate at critical stages of drug R&D. By accelerating the pace of drug discovery and development, XtalPi aims to contribute to a healthier society worldwide.Founded in 2014 by a group of quantum physicists at MIT, XtalPi has since grown into an elite team of researchers with multi-disciplinary expertise in physics, chemistry, pharmaceutical R&D, and algorithm design. XtalPi has received much recognition for its cutting-edge technologies, its innovative solutions, and the breadth of potential applications of its offerings across the pharmaceutical value chain, which has allowed it to gain industry approval and establish strategic partnerships with several top international pharmaceutical companies.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series A, Seed, Angel
- Geography: China, United States, Japan
Investor stats
- Total investments: 25
- Round size: Seed $1.4M–$15M; Series A $11M–$30M
- Lead/follow: 44% lead, 56% follow
Portfolio highlights
- Prenetics — CircleDNA is an at-home, non-invasive DNA test providing health insights across 500+ reports based on your unique genetic blueprint.
- Rabbitpre — Rabbitpre is a big data-driven technology marketing company.
- Xellar Biosystems — Xellar Biosystems is a wet artificial intelligence biotechnology company that provides analysis of drug testing and treatment.
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, The Netherlands, Germany
Investor stats
- Total investments: 127
- Round size: Series A $8.8M–$65M; Series B $15M–$120M; Series C $21M–$75M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely still investing — raised $786M in 2023
Portfolio highlights
- Okami Medical — Okami Medical is a medical device company with a mission to address the evolving needs of patients and physicians through the development of innovative, versatile, and intuitive devices for the occlusion of peripheral vessels.
- ProVerum Medical — The ProVee stent from Proverum Medical uses 3-D geometry which mirrors and engages with the anatomy of the prostate. The system alleviates Lower Urinary Tract Symptoms (LUTS) by opening the prostatic urethra, applying radial force to the prostatic lobes.
- Endovascular Engineering — Endovascular Engineering is a preclinical stage company developing novel mechanical thrombectomy solutions to address peripheral indications.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 170
- Round size: Seed $2.4M–$22M; Series A $5.6M–$49M; Series B $15M–$100M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Anjuna — Anjuna confidential cloud software establishes a secure enclave that isolates and encrypts applications and data in runtime, at rest, and on the network for end-to-end data protection
- Biolinq — Introducing a revolutionary platform for metabolic health.
- Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
Inserm Transfert Initiative is a seed stage life science vehicle currently managing about €4.2M for the financing of new biotech companies. Inserm Transfert Initiative is the new investment vehicle of INSERM in France.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Series B, Seed
- Geography: France, Switzerland, United States
Investor stats
- Total investments: 22
- Round size: Seed $2.7M–$3.6M; Series A $1.1M–$35M; Series B $2.2M–$60M
- Lead/follow: 5% lead, 95% follow
Portfolio highlights
- Eyevensys — Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasiveprocedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability.They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures.
- VectivBio — Explore Ironwood Pharmaceuticals' commitment to GI health with innovative therapies, patient-focused research, and a vision to improve digestive disease treatment.
- Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 96
- Round size: Seed $1.3M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- Perfood — Perfood is a digital therapeutic startup that identifies what actions need to take on a personalized level, to prevent or fight diseases. Using sensors, lab results, and holistic analyses, they derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. They call this approach digitaltherapeutics. A digital solution that is just as effective as a drug. But without side effects.
- ArrePath — ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections.
- Nuevocor — Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts.
Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: Switzerland
Investor stats
- Total investments: 10
- Round size: Seed $1.6M–$7.2M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Hemostod — Developing universal platelets and next-generation diagnostics
- DigeHealth — DigeHealth's approach to monitoring gut health using bowel noises and body measurements could provide some really valuable insights into digestive well-being.
- Allegria Therapeutics — Allegria Therapeutics operates as a biotech company.
The William K. Warren Foundation focuses on people and aims to improve the human condition on earth as a response to and in thanksgiving.The foundation's goal is to make medical care available to all patients utilizing Saint Francis Health System, and to this end, it annually supports various medical programs. In addition to the hospitalsand clinics, the foundation created The William K. Warren Medical Research Centre in 1973, which provides funds to medical investigators who participate in advanced medical research and creates environments that allow for the best possible delivery of care.
Show more...Investment focus
- Industry: Machine Learning, Health Care, Artificial Intelligence
- Stage:Seed, Series A, Series B
- Geography: United States, Switzerland
Investor stats
- Total investments: 7
- Lead/follow: no public data
Portfolio highlights
- KetoSwiss — KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases. It develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolicdysfunction (such as Alzheimer's disease). KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem.
- Spring Health — Eliminating barriers to mental healthcare. Clinically-proven technology with world-class providers to deliver precisely what your employees need.
- iRecommend Software™ — Play the best slots, exciting sports betting, and real-time live dealer games at Pin Up Casino India. Get your welcome package worth up to $5,000 plus 250 free spins and kick off your winning journey today!
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Ortho Innovations is a manufacturer of orthopedic products. The company's products are the elbow brace, knee brace, hyperflexion elbow, wrist, flexion-extension, wrist pronation, supination, and hip abduction orthosis.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Seed
- Geography: Switzerland
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- KetoSwiss — KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases. It develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolicdysfunction (such as Alzheimer's disease). KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem.
Healthspan Capital is an early-stage longevity venture capital firm that invests in biotechnology startups developing therapies to slow or reverse aging.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 7
- Lead/follow: no public data
Portfolio highlights
- KetoSwiss — KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases. It develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolicdysfunction (such as Alzheimer's disease). KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem.
- ImmuneAGE Bio — ImmuneAGE Bio is the first drug discovery platform company focused on immune system rejuvenation.
- Reservoir Neuroscience — Reservoir Neuroscience is a biopharma company that develops novel therapeutics to repair dysfunctional blood vessels in the brain. Reservoir Neuroscience was founded in 2019 and is based in Emeryville, California.
Calm/Storm is an exclusive founder network and venture capital firm. We invest in purpose driven founders changing our life & health for the better. Headquartered in Vienna, Austria we invest in early-stage companies all over Europe and the US. We focus on the pre-seed and seed stages but also invest up to Series A.
Show more...Investment focus
- Industry: Health Care, Wellness, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, Germany, Austria
Investor stats
- Total investments: 113
- Lead/follow: no public data
Portfolio highlights
- aiomics — Aiomics | Back to your calling.Across Europe, healthcare providers lose hours every day to fragmented documentation—handwritten notes, scanned PDFs, dictations, disconnected IT systems. The result: burnout, missed revenue, and patients feeling like they’re asked the same question three times.Aiomics changes this. Our AI-driven co-pilot capturesevery clinical detail—speech, handwriting, digital notes—and validates it in real time with a human-in-the-loop process. Interactive checklists surface missing information before the patient leaves, and audit-ready records flow straight back into existing systems. Built for GDPR, MDR, and the EU AI Act from day one, Aiomics makes documentation complete, compliant, and instantly usable.We don’t replace EHRs—we make them better. From admission and discharge reports to insurer forms, from therapist briefings to patient-friendly letters, Aiomics turns paperwork from a burden into an asset. For providers, that means fewer errors, faster reimbursements, and—most importantly—more time at the bedside.Our mission: to empower healthcare professionals by removing administrative burdens and elevating their decision-making with trusted AI guidance—so they can reconnect with why they chose this vocation in the first place.Who we are: Aiomics is co-founded by Dr. Sven Jungmann, a physician with frontline experience of administrative overload; Dr. Nikita Tarasov, a physicist and data scientist; and a lawyer who scaled one of Europe’s largest digital service companies. Together, we unite empathy, technical mastery, and regulatory expertise to build the trusted co-pilot for Europe’s healthcare providers.
- ThinkSono — ThinkSono is a company at the cutting edge of medicine and technology.
- Nolea Health — As a clinician with Nolea you can set your own schedule, work with as many healthcare companies as you want, hold all of your credentials in one single sharable wallet, access new educational resources, and receive community feedback.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 204
- Lead/follow: no public data
Portfolio highlights
- Rhygaze — Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
- Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
- Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.
Grazia Equity is a venture Capital firm investing in innovative, technology driven startups with high potential.Based in Stuttgart (Germany), Grazia has been supporting a large number of mostly young companies, often from their foundation to the Initial Public Offering or eventual sale. In contrast to other venture capital firms, theypredominantly work with their own capital that they invest as entrepreneurs.
Show more...Investment focus
- Industry: Internet, E-Commerce, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: Germany, United States, Switzerland
Investor stats
- Total investments: 81
- Lead/follow: no public data
Portfolio highlights
- Q.ANT — Q.ANT develops photonic processors for AI and high-performance computing, utilizing light for information processing. The company also produces quantum sensors offering ultra-high magnetic field sensitivity in a compact form factor. These products aim to enable more intelligent and sustainable systems across various sectors like data centers,aerospace, and medical technology.
- Vytal — Start the Packaging Revolution! We are offering smart & reusable To-Go Packaging-as-a-Service to gastronomy clients & consumers.In Germany the consumption of take-away, convenience and delivery food & drinks is responsible for about 281 kilotons of single-use packaging waste for immediate consumption and is growing at double digitrates. Most of the time, To-Go food containers, snack boxes or coffee cups have a very short life-span of only 30 minutes after which they are tossed into trash (or litter parks, beaches & the ocean). This is not only a giant waste of economic resources as each single use costs between 15 and up to 0,60€ for a stable bowl/box with a lid. It is a horrendous waste of environmental resources (wood, water, crude oil, metals & energy) that are used to produce this packaging. Therefore, a single use packaging not weighing more than 30 grams can easily come with an ecological backpack of more than 8 kilograms when taking into account all the resources used in production (material intensities taken from Wuppertal Institute for Climate, Environment and Energy). Looking at GHG emissions, the picture is similarly bleak: Using CO2 emission factors and the detailed material mix of the single-use packaging waste analyzed by NABU (German Nature and Biodiversity Conservation Union), the 281 thousand tons waste from To-Go consumption generated around 556 thousand tons of CO2 or the equivalent of 195k passenger cars per year (assuming an average distance travelled of 15,000km). With the expected rise of take-away, convenience and delivery food, the related emissions are expected to increase at double digit rates as waste volume is expected to increase and as we saw a shift to plastics relative to cardboard or other materials. While there is a growing awareness of the problem, especially in Germany, there is no scalable solution yet and the commonly used alternative of nature-based & ‘biodegradable’ materials like bagasse or PLA also require many resources for production & transport, and have to be incinerated or go to landfill after use as there is currently no way to compost them.
- Lumotive — Lumotive is a Seattle-based startup company developing high performance, solid-state lidar for autonomous systems in the automotive, UAV, robotics and related industries. The company's revolutionary beam-steering technology leverages Liquid Crystal Metasurfaces (or LCMs) implemented in mature semiconductor manufacturing processes to deliversmall, inexpensive 3D perception systems with unprecedented performance and reliability. For more information, visit us at www.lumotive.com.
Boundary Holding is a European deep tech investment firm with presence in Luxembourg and France that invests in technologies enabling 4th industrial revolution.
Show more...Investment focus
- Industry: Drones, Robotics, Artificial Intelligence
- Stage:Seed, Series A
- Geography: Switzerland, India, France
Investor stats
- Total investments: 40
- Round size: Seed $18k–$4.7M
- Lead/follow: 10% lead, 90% follow
- Last fund: May invest from a new fund soon — last raise in 2016
Portfolio highlights
- Aero41 — Aero41 is developing a drone entirely dedicated to crop protection, a flexible and intelligent platform that will integrate AI and collect data to make crop protection more and more eco-responsible while being effective to ensure the necessary yields.
- Neo Medical — Neo aims at transforming the current approach to spinal surgery by providing a unique answer to the worldwide strive for healthcare cost optimization through efficient, versatile and high quality systems.
- Remidio Innovative Solutions — Remidio is engaged in designing & developing Smart, Innovative & Disruptive Imaging Technologies in Vision Care, using a product development approach called “Design Thinking”.As part of the Design Thinking process, Remidio takes into account different facets of a customer’s experience with a product, as part of its overall productdesign approach, with the intent of inventing a new customer experience with the product.Customers can be an amazing resource to glean insight and understanding, but they are generally not able to articulate their latent and anticipated needs. Remidio hence focuses on making quick functional prototypes, that can then be given to the customer to understand these latent needs while observing their use of the prototypes.Founded by professionals with a passion for product innovation, Remidio is currently focussed on creating game changing products and solutions in the ophthalmology space.We look at constraints posed by a developing nation context- infrastructure, skilled resources and affordable pricing as an opportunity to innovate.We bring to market very high quality products that are reliable and extremely simple to use.
Baszucki Group directs resources toward the greater good through mission-driven investments that improve human health, governance, and the health of our planet.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Seed
- Geography: Switzerland
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- KetoSwiss — KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases. It develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolicdysfunction (such as Alzheimer's disease). KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem.
Reference Capital is a privately held advisory firm dedicated to researching and investing in disruptive technologies which will transform the world we live in. Our team is composed of seasoned VC investors and family office managers primarily based in Geneva, Switzerland.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series C, Series B
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 54
- Lead/follow: no public data
Portfolio highlights
- Wayve — Wayve are pioneering an AI-centric approach to self-driving, inspired by our vision of a smarter, safer and more sustainable world.
- All Day Kitchens — Virtual Kitchen operates as a platform that empowers restaurants to take full advantage of the delivery opportunity. Its delivery-optimized kitchens and technology unlock delivery coverage with minimal upfront investment. The company was founded in 2018 and is headquartered in San Francisco, California.
- Kingdom Supercultures — Kingdom Supercultures create microbial cultures that help food manufacturers to create new foods with boosted benefits. It re-assembles nature's microbes into new combinations, creating plant-based foods that taste like dairy, low-alcohol beverages with full flavor, and natural preservatives that work as well as artificial ones.They workwith clients across diverse industries including food, beverage, personal care, beauty, and more. Their technology comprises an expansive biobank of GRAS microbial strains, high-resolution strain characterization, and new algorithms for predicting and assembling microbial communities.
R42 Group is a venture fund and an institute which invents, invests and informs covering AI, deep science, 5G mobile, biotech and fintech.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Information Technology
- Stage:Seed, Pre-Seed
- Geography: United Kingdom, United States, Austria
Investor stats
- Total investments: 27
- Lead/follow: no public data
Portfolio highlights
- Healx — At Healx we use AI drug discovery to develop new treatments for rare diseases. We bring treatments from prediction to patient.
- xWatts — xWatts is an intelligent energy management software that reduces energy costs and emissions in commercial buildings.
- Senisca — Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing.
Viva BioInnovator (VBI) is the specialized investment and incubation arm of Viva Biotech Holdings. We focus on the initial creation and development of biotech startups across all indications and drug types. During the early stages of drug discovery, we can nurture and accelerate a startup's growth from idea to clinical program. VBI'sunique investment and incubation model started out of necessity in 2014. Our roots are in drug discovery services, where we operate world-leading and proprietary drug discovery platforms. While serving big pharma customers from around the globe, we came to realize the huge demand from many entrepreneurs who have great ideas but cannot receive funding to advance their plan due to lack of data. We saw the value in many of these innovative ideas and provided our CRO drug discovery services, operational support, and monetary backing to help these creative scientists embark on the "0 to 1" transformation. This spark launched our "equity for service (EFS)" investment and incubation model. VBI is based in Shanghai, with an office in Boston and personnel in California. As of early 2019, VBI has invested in over 30 companies out of the hundreds of proposals submitted for review and we plan to invest at a rapid pace in the years to come. The majority of our current portfolio companies are US based, but we are open to proposals globally and are excited to see new ideas that fit our investment strategy. If you would like to learn more about us, please visit: www.vivabioinnovator.com Or send an email to innovation@vivabiotech.com If you would like to learn more about our parent company, Viva Biotech, please visit: www.vivabiotech.com
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United States, Canada, China
Investor stats
- Total investments: 26
- Round size: Seed $2.6M–$20M; Series A $250k–$20M; Series B $4.3M–$100M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
- Vincere Biosciences — Vincere Biosciences is a JLABS incubator company whose mission is to develop drugs to halt the progression of Parkinson's disease (PD).
- TechnoDerma Medicines — TechnoDerma Medicines focuses on the research and development of innovative skin drugs for external use.
Medical Investor funding in Switzerland at a glance
Stats across 447 deals from 432 investors.
Access all 432 investors in Switzerland Medical startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Medical Investors in Switzerland investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 432 investors investing in Switzerland Medical startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!